Clinical Trial Update: Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update evaluating anti-CD19 CAR-T therapy used as a bridging therapy to hematopoietic stem cell transplant for CD19+ B-cell malignancie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Lymphoma

Drugs mentioned

• Anti-CD19 CAR-T therapy (CAR-T cell therapy targeting CD19)

Snippet

Sponsor: Wuhan Sian Medical Technology Co., Ltd | Conditions: Acute Lymphoblastic Leukemia, B Cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN